SCHEMBL23405779

SCHEMBL23405779

COc1ccc(CNc2nc(N[C@H](C)C(F)(F)F)nc(C3=C(F)C(=O)CCC3)n2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.46
ALDH1A1 P00352 2/20 0.46
KDM4E B2RXH2 1/20 0.46
POLB P06746 1/20 0.46
HPGD P15428 1/20 0.46
TSHR P16473 1/20 0.46
HSD17B10 Q99714 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
MAPT P10636 6/20 0.39
TP53 P04637 3/20 0.39
FABP4 P15090 1/20 0.38
USP2 O75604 1/20 0.38
VNN1 O95497 2/20 0.37
MEN1 O00255 1/20 0.36
GAA P10253 1/20 0.36
KMT2A Q03164 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C9 P11712 1/20 0.36
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23405781 1.00 SMN1; SMN2 (0.46) SMN1; SMN2ALDH1A1KDM4EPOLBHPGD
SCHEMBL23431958 0.91 ALDH1A1 (0.44) SMN1; SMN2ALDH1A1KDM4EPOLBHPGD
SCHEMBL23405825 0.87 KCNH3 (0.49) SMN1; SMN2ALDH1A1L3MBTL1MAPTMEN1
SCHEMBL23405822 0.87 KCNH3 (0.49) SMN1; SMN2ALDH1A1L3MBTL1MAPTMEN1
SCHEMBL20814306 0.85 ALDH1A1 (0.43) SMN1; SMN2ALDH1A1KDM4EPOLBHPGD
SCHEMBL29103780 0.84 ALDH1A1 (0.43) SMN1; SMN2ALDH1A1KDM4EPOLBHPGD
SCHEMBL20814303 0.84 SMN1; SMN2 (0.41) SMN1; SMN2ALDH1A1KDM4EPOLBHPGD
SCHEMBL23405835 0.83 IDH1 (0.41) IDH1IDH2
SCHEMBL23405832 0.83 IDH1 (0.41) IDH1IDH2
SCHEMBL23431959 0.83 SMN1; SMN2 (0.43) SMN1; SMN2ALDH1A1KDM4EPOLBHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250223267-A1 CYCLOOLEFIN SUBSTITUTED HETEROAROMATIC COMPOUNDS AND THEIR USE HUTCHISON MEDIPHARMA LIMITED (CN) 2025-07-10 US disclosed
US-12234211-B2 Cycloolefin substituted heteroaromatic compounds and their use HUTCHISON MEDIPHARMA LIMITED (CN) 2025-02-25 US disclosed
US-20220372005-A1 CYCLOOLEFIN SUBSTITUTED HETEROAROMATIC COMPOUNDS AND THEIR USE HUTCHISON MEDIPHARMA LIMITED (CN) 2022-11-24 US disclosed
US-11414390-B2 Cycloolefin substituted heteroaromatic compounds and their use HUTCHISON MEDIPHARMA LIMITED (CN) 2022-08-16 US disclosed
US-20210363115-A2 CYCLOOLEFIN SUBSTITUTED HETEROAROMATIC COMPOUNDS AND THEIR USE HUTCHISON MEDIPHARMA LIMITED (CN) 2021-11-25 US disclosed
US-20210363115-A2 CYCLOOLEFIN SUBSTITUTED HETEROAROMATIC COMPOUNDS AND THEIR USE HUTCHISON MEDIPHARMA LIMITED (CN) 2021-11-25 US disclosed
US-20210163426-A1 CYCLOOLEFIN SUBSTITUTED HETEROAROMATIC COMPOUNDS AND THEIR USE HUTCHISON MEDIPHARMA LIMITED (CN) 2021-06-03 US disclosed
CN-111132967-A Cyclic olefin substituted heteroaromatic ring compound and application thereof 和记黄埔医药(上海)有限公司 2020-05-08 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210363115-A2 CYCLOOLEFIN SUBSTITUTED HETEROAROMATIC COMPOUNDS AND THEIR USE CYP4F11, CYP11B1, CYP11B2 SMN1; SMN2 2853/4885ALDH1A1 1250/4885KDM4E 4630/4885
US-20220372005-A1 CYCLOOLEFIN SUBSTITUTED HETEROAROMATIC COMPOUNDS AND THEIR USE CYP4F11, CYP11B1, CYP11B2 SMN1; SMN2 2809/4885ALDH1A1 1756/4885KDM4E 4772/4885
US-20250223267-A1 CYCLOOLEFIN SUBSTITUTED HETEROAROMATIC COMPOUNDS AND THEIR USE CYP4F11, CYP11B1, CYP11B2 SMN1; SMN2 2809/4885ALDH1A1 1756/4885KDM4E 4772/4885
US-12234211-B2 Cycloolefin substituted heteroaromatic compounds and their use CYP4F11, CYP11B1, CYP11B2 SMN1; SMN2 2809/4885ALDH1A1 1756/4885KDM4E 4772/4885
US-11414390-B2 Cycloolefin substituted heteroaromatic compounds and their use CYP4F11, CYP11B1, CYP11B2 SMN1; SMN2 2814/4885ALDH1A1 1572/4885KDM4E 4773/4885
US-20210163426-A1 CYCLOOLEFIN SUBSTITUTED HETEROAROMATIC COMPOUNDS AND THEIR USE CYP4F11, CYP11B1, CYP11B2 SMN1; SMN2 2814/4885ALDH1A1 1572/4885KDM4E 4773/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.